The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the promising new agents for patients with myelofibrosis?

During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, What are the promising new agents for patients with myelofibrosis?

What are the promising new agents for patients with myelofibrosis?

In this video, Mesa outlines the new agents available for the treatment of patients with myelofibrosis, including the JAK inhibitors ruxolitinib and fedratinib, and another two JAK inhibitors currently under development, momelotinib and pacritinib. Mesa then moves on to discuss other options beyond JAK inhibition, including CPI-0610, navitoclax, imetelstat, bomedemstat, and luspatercept.

Share: